查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1992763

進行性及復發性卵巢癌市場：依治療方法、給藥途徑、治療線、生物標記狀態及最終用戶分類－2026-2032年全球市場預測

Advanced Recurrent Ovarian Cancer Market by Treatment Type, Administration Route, Line Of Therapy, Biomarker Status, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，進行性復發性卵巢癌市值為 16.8 億美元，預計到 2026 年將成長至 18.5 億美元，複合年成長率為 9.69%，到 2032 年將達到 32.2 億美元。

主要市場統計數據
基準年 2025 16.8億美元
預計年份：2026年 18.5億美元
預測年份 2032 32.2億美元
複合年成長率 (%) 9.69%

觀點不斷變化的臨床、監管和商業性環境，為進行性和復發性卵巢癌的相關人員提供策略決策框架。

進行性和復發性卵巢癌的治療和商業格局瞬息萬變，臨床範式不斷轉變，相關人員的關注度也日益提高。本執行摘要介紹了本研究的核心主題，重點闡述了標靶治療、生物標記主導的治療以及醫療服務模式的進步如何融合，從而改變復發性患者的治療路徑。此外，本概要還概述了監管壓力、支付方期望以及供應鏈的考量，這些因素共同影響臨床進展並最終決定商業性可行性。

先進的診斷技術、不斷發展的給藥途徑以及支付方主導的證據要求，正在如何重塑治療模式和商業化策略？

由於治療方法的創新、診斷技術的精準化以及醫療服務體系的重塑，進行性和復發性卵巢癌的治療模式正在發生變革性變化。新型標靶治療療法和聯合治療正在重新定義療效預期與耐受性之間的權衡，而伴隨診斷和同源重組缺陷（HRD）檢測的廣泛應用則使得個人化治療方法方案成為可能。因此，傳統的化療為中心的治療路徑正在調整，優先考慮在分子層面上明確標標靶藥物和免疫療法聯合治療。

2025 年貿易政策轉變對癌症治療供應鏈韌性、採購慣例和市場定位的策略影響。

2025年關稅的實施和貿易政策的轉變為進行性和復發性卵巢癌生態系統中的相關人員帶來了顯著的營運和策略複雜性。供應鏈經理和採購團隊正在透過審查其原料藥、成品和關鍵診斷劑的籌資策略來應對這些挑戰，以降低成本波動和交貨延遲的風險。因此，擁有垂直整合供應鏈和多元化製造地的公司能夠更柔軟性應對關稅的短期影響，而其他公司則正在加快供應商合格和緊急時應對計畫。

從綜合細分觀點來看，治療分類、給藥途徑、治療線、生物標記定義的隊列、醫療保健環境和分銷管道如何相互作用，從而影響採用趨勢。

細分市場分析揭示了治療決策、給藥途徑選擇、在治療體系中的定位、生物標記狀態、醫療機構以及分銷合作夥伴如何相互交織，共同塑造臨床和商業性發展軌跡。根據治療類型，市場涵蓋化療（包括含鉑類藥物和非含鉑類藥物） 、荷爾蒙療法療法（包括Aromatase抑制劑和雌激素受體調節） 、免疫療法（包括癌症疫苗和查核點抑制劑）、手術（作為關鍵干預手段）以及標靶治療（包括抗血管新生藥物和PARP抑制劑）。每類藥物都有其獨特的療效特徵、耐受性考量以及影響臨床應用所需的實證醫學證據。

差異化的打入市場策略受到區域挑戰以及世界各地不同地區支付方的多樣性、診斷能力和監管差異的影響。

區域趨勢對臨床路徑、監管預期、診斷方法應用和商業化策略有顯著影響。在美洲，支付方的多樣性和集中化的專科藥房網路凸顯了衛​​生經濟學證據和病患支持計畫對於確保醫保覆蓋和就醫便利的重要性。在歐洲、中東和非洲（EMEA），不同的法規環境和報銷框架要求制定符合各國支付方標準和區域醫療環境的打入市場策略。同時，各地區診斷基礎設施和分子檢測的可近性也存在顯著差異。在亞太地區，部分國家診斷能力的快速擴張和癌症治療公共投入的增加為早期市場准入創造了機遇，但當地的監管和定價壓力往往要求企業採用適應性強的商業化模式。

透過臨床差異化、診斷夥伴關係和策略聯盟來塑造競爭定位，可以精準定位患者並與支付方建立聯繫。

在進行性復發性卵巢癌領域，競爭格局主要集中在跨國製藥公司、專注於腫瘤生物技術的公司、提供基於生物標記療法的診斷公司以及新興的契約製造和分銷合作夥伴之間。主要企業透過設計強調有意義的無惡化生存期和患者報告結局的臨床項目、推進基於生物標記的適應症拓展以及投資伴隨診斷來鎖定特定患者群體，從而脫穎而出。創新生物技術公司經常致力於聯合治療和新型作用機制的研發，以克服抗藥性問題，而老字型大小企業則利用其規模、商業基礎設施和全球監管經驗來加速產品上市。

產業領導者可以採取切實可行的策略步驟來整合診斷、增強證據產生、加強供應鏈並加快跨市場保險公司的接受度。

產業領導者應優先採取一系列切實可行的步驟，以掌握治療和商業性機遇，同時降低風險。首先，將生物標記策略整合到臨床開發的各個階段，從最初的人體試驗到擴大適應症的試驗，以確保及時獲得伴隨診斷和明確的患者選擇標準。其次，儘早投資於真實世界數據 (RWE) 的生成和衛生經濟學研究，以支持與保險公司的對話，並展現超越傳統療效終點的後續價值。第三，設計開發方案時，應將給藥途徑作為商業性差異化因素，並在臨床可行的情況下評估口服和皮下製劑，以支持門診治療和提高用藥依從性。

為了確保實用性，我們採用透明的混合方法研究方法，結合了專家的直接知識、對二手資訊的嚴格檢驗以及情境分析。

本報告的調查方法整合了對臨床專家、支付方和商業化負責人的定性訪談、對同行評審期刊和監管文件的文獻綜述，以及對診斷和治療產品線的結構化整合。主要資訊包括對腫瘤科臨床醫生、醫院藥劑師和市場准入專家的半結構化訪談，旨在檢驗臨床路徑、識別推廣障礙並提取支付方重視的證據重點。次要研究著重於監管指導文件、臨床試驗註冊數據和已發表的結果研究，以支持治療的療效、安全性和診斷效用。

強調診斷主導的個人化、實證發展和供應鏈韌性的綜合洞察是永續商業性成功的關鍵支柱。

總之，進行性和復發性卵巢癌的生態系統正處於一個十字路口，診斷主導的個體化治療、治療創新和支付主導的證據需求在此交匯，勢必重塑臨床和商業性路徑。積極整合生物標記策略、優先考慮符合支付方需求的證據產生、並最佳化以患者為中心的給藥方案的相關人員將獲得競爭優勢。此外，供應鏈設計的韌性和區域性調適策略對於應對政策相關的成本壓力和不同的區域報銷環境至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療方法進行性和復發性卵巢癌市場

  • 化療
    • 非含鉑類藥物
    • 含鉑類藥物
  • 荷爾蒙療法
    • Aromatase抑制劑
    • 雌激素受體調節
  • 免疫療法
    • 癌症疫苗
    • 查核點抑制劑
  • 外科手術
  • 分子標靶治療
    • 抗血管新生藥物
    • PARP抑制劑

第9章：按給藥途徑分類的進行性和復發性卵巢癌市場

  • 腹腔內
  • 靜脈
  • 口服
  • 皮下

第10章：依治療階段進行性和復發性卵巢癌市場

  • 從第四行開始
  • 第二行
  • 第三行

第11章：按生物標記狀態進行性和復發性卵巢癌市場

  • 同源重組缺陷陰性
  • 同源重組缺陷陽性

第12章：進行性和復發性卵巢癌市場：按最終用戶分類

  • 門診部
  • 癌症中心
  • 醫院
  • 專科診所

第13章：進行性和復發性卵巢癌市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：進行性和復發性卵巢癌市場：按組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：進行性和復發性卵巢癌市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國進行性和復發性卵巢癌市場

第17章：中國進行性及復發性卵巢癌市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Celsion Corporation
  • Clovis Oncology Inc.
  • Debiopharm International SA
  • Eli Lilly and Company
  • Exelixis Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline plc
  • ImmunoGen Inc.
  • Johnson & Johnson Services, Inc.
  • Kintara Therapeutics Inc.
  • Merck & Co., Inc.
  • Mirati Therapeutics Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Vivesto AB
Product Code: MRR-1A1A064BFFBB

The Advanced Recurrent Ovarian Cancer Market was valued at USD 1.68 billion in 2025 and is projected to grow to USD 1.85 billion in 2026, with a CAGR of 9.69%, reaching USD 3.22 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.68 billion
Estimated Year [2026] USD 1.85 billion
Forecast Year [2032] USD 3.22 billion
CAGR (%) 9.69%

A focused orientation to the evolving clinical, regulatory, and commercial context that frames strategic decisions for advanced recurrent ovarian cancer stakeholders

Advanced recurrent ovarian cancer presents a rapidly evolving therapeutic and commercial environment defined by shifting clinical paradigms and intensifying stakeholder scrutiny. This executive summary introduces the core themes of the research, focusing on how advances in targeted modalities, biomarker-driven care, and care delivery models converge to change treatment pathways for patients with recurrent disease. The introduction also frames regulatory pressures, payer expectations, and supply chain considerations that intersect with clinical advances to shape commercial viability.

In addition, the introduction outlines the methodological approach and scope used to examine therapeutic classes, routes of administration, lines of therapy, biomarker-defined subpopulations, care settings, and distribution channels. By establishing a clear problem statement and analytical boundaries, the introduction prepares readers for the deeper analysis that follows, while highlighting the practical implications for development teams, commercial leaders, and investor groups. Ultimately, this section positions the reader to interpret subsequent insights with an understanding of clinical context and stakeholder priorities.

How precision diagnostics, administration route evolution, and payer-driven evidence requirements are reshaping treatment paradigms and commercialization strategies

The therapeutic landscape for advanced recurrent ovarian cancer is undergoing transformative shifts driven by therapeutic innovation, precision diagnostics, and care delivery redesign. Novel targeted therapies and combination regimens are redefining efficacy expectations and tolerability trade-offs, while companion diagnostics and broader adoption of homologous recombination deficiency testing are enabling more individualized treatment selection. As a result, traditional chemotherapy-dominant pathways are being recalibrated in favor of targeted agents and immunotherapy combinations where molecularly appropriate.

Concurrently, payer policies and real-world evidence requirements are prompting manufacturers to integrate health economics and outcomes research earlier in development. This trend increases the premium on robust, longitudinal outcome data and on demonstrating value across multiple lines of therapy. Moreover, the route of administration is becoming a strategic differentiator; therapies that enable oral or subcutaneous delivery offer advantages in patient convenience and outpatient management, thereby affecting adoption and channel preference. Taken together, these shifts require cross-functional alignment among clinical development, diagnostics partnerships, market access, and commercial operations to capture emerging opportunities effectively.

Strategic consequences of 2025 trade-policy shifts on supply chain resilience, procurement practices, and commercial positioning in oncology therapeutics

The introduction of tariffs and trade-policy shifts in 2025 has introduced discrete operational and strategic complexity for stakeholders across the advanced recurrent ovarian cancer ecosystem. Supply chain managers and procurement teams have responded by reassessing sourcing strategies for active pharmaceutical ingredients, finished products, and key diagnostic reagents to mitigate cost volatility and potential delivery delays. As a consequence, firms with vertically integrated supply chains or diversified manufacturing footprints have greater flexibility to absorb near-term tariff impacts, while others are accelerating supplier qualification and contingency planning.

From a commercial perspective, tariff-related cost pressures are increasing scrutiny on price versus value narratives when engaging payers and hospital procurement committees. Manufacturers are therefore prioritizing evidence generation that demonstrates real-world benefits, reductions in downstream resource use, and patient-centered outcomes to sustain favorable formulary positioning. In parallel, distributors and specialty pharmacies have re-evaluated inventory practices and freight optimization to maintain continuity of care for patients on critical therapies. In summary, tariff-driven dynamics have amplified the importance of resilient manufacturing, robust value communication, and proactive supply chain risk management.

Integrated segmentation perspective showing how treatment class, administration route, therapy line, biomarker-defined cohorts, care settings, and distribution channels interact to shape adoption

Segment-level insight reveals how therapeutic decisions, administration preferences, line-of-therapy placement, biomarker status, care settings, and distribution partners collectively shape clinical and commercial trajectories. Based on treatment type, the market spans chemotherapy-where differentiation exists between platinum based agents and non-platinum agents-hormone therapy including aromatase inhibitors and estrogen receptor modulators, immunotherapy comprising cancer vaccines and checkpoint inhibitors, surgery as a critical intervention, and targeted therapy that includes anti-angiogenic agents and PARP inhibitors; each class presents distinct efficacy profiles, tolerability considerations, and evidence-generation needs that influence adoption across clinical practices.

Based on administration route, therapeutic uptake is influenced by the balance between inpatient infusion requirements and the growing preference for oral or subcutaneous options that support outpatient care and patient convenience. Based on line of therapy, strategic positioning varies across fourth and beyond, second line, and third line settings, with organizations tailoring clinical development and sequencing studies to demonstrate meaningful benefit where unmet need and reimbursement potential intersect. Based on biomarker status, differentiation is most apparent in BRCA mutant populations and across homologous recombination deficiency positive and negative subgroups, which drive diagnostic integration and targeted therapy eligibility. Based on end user, adoption dynamics differ among ambulatory care centers, cancer centers, hospitals, and specialty clinics as each setting has unique clinical workflows, budget cycles, and procurement practices. Based on distribution channel, dynamics across hospital pharmacies, online pharmacies, and retail pharmacies affect patient access, channel economics, and adherence support strategies. Integrating these segmentation dimensions uncovers practical implications for clinical development, diagnostics alignment, pricing strategy, and channel-specific commercialization planning.

Regional imperatives and differentiated market entry strategies driven by payer diversity, diagnostic capacity, and regulatory variance across global geographies

Regional dynamics materially influence clinical pathways, regulatory expectations, diagnostic adoption, and commercialization approaches. In the Americas, payer heterogeneity and concentrated specialty pharmacy networks emphasize the importance of health economic evidence and patient support programs to secure coverage and access. In Europe, Middle East & Africa, diverse regulatory environments and reimbursement frameworks mean that market entry strategies must be tailored to national payer criteria and regional centers of excellence, while diagnostic infrastructure and access to molecular testing vary widely across the region. In the Asia-Pacific region, rapid expansion of diagnostic capabilities in certain countries and increasing public investment in oncology care create opportunities for early market entry, though local regulatory and pricing pressures often require adaptive commercialization models.

Consequently, successful regional strategies prioritize early stakeholder mapping, investment in diagnostic partnerships where biomarker-driven therapies matter most, and flexible channel strategies that reflect local distribution and reimbursement realities. Transitional considerations include local evidence generation to support formulary decisions and partnerships with regional clinical leaders to demonstrate real-world utility across diverse healthcare systems.

Competitive positioning shaped by clinical differentiation, diagnostics partnerships, and strategic alliances that enable precise patient targeting and payer engagement

Competitive dynamics in advanced recurrent ovarian cancer are concentrated among multinational pharmaceutical companies, specialized oncology biotechs, diagnostic firms that enable biomarker-guided care, and emerging contract manufacturing and distribution partners. Leading developers differentiate through clinical program design that emphasizes meaningful progression-free and patient-reported outcomes, the pursuit of biomarker-driven label expansions, and investment in companion diagnostics to secure precise patient populations. Biotech innovators frequently pursue combination regimens and novel mechanisms to address resistant disease, while established companies leverage scale, commercial infrastructure, and global regulatory experience to accelerate launch readiness.

Collaborations and licensing arrangements between therapeutic developers and diagnostic companies have become pivotal, enabling synchronized regulatory submissions and payer narratives. In addition, strategic alliances with specialty pharmacy networks and hospital systems support adherence programs and optimize channel-level distribution. Accordingly, companies that align clinical differentiation with a coherent diagnostics and access strategy will be better positioned to navigate complex reimbursement pathways and deliver sustained uptake in clinically appropriate patient cohorts.

Practical strategic steps industry leaders can implement to integrate diagnostics, bolster evidence generation, fortify supply chains, and accelerate payer acceptance across markets

Industry leaders should prioritize a set of actionable initiatives to capture therapeutic and commercial opportunities while mitigating risk. First, integrate biomarker strategy into clinical development from first-in-human through label-expansion studies to ensure timely companion-diagnostic availability and clear patient selection criteria. Second, invest in real-world evidence generation and health economics research early to support payer conversations and to demonstrate downstream value beyond traditional efficacy endpoints. Third, design development programs to consider administration route as a commercial differentiator, evaluating oral or subcutaneous formulations where clinically feasible to support outpatient care and adherence.

Furthermore, companies should strengthen supply chain resilience by diversifying sourcing, qualifying multiple manufacturing partners, and maintaining transparent logistics contingency plans to limit exposure to tariff or trade-policy disruptions. Establishing strong relationships with specialty pharmacies, hospital systems, and ambulatory care networks will facilitate access programs and channel-specific patient support. Finally, adopt a data-driven market access playbook that aligns evidence generation, pricing strategy, and stakeholder engagement across targeted regions to accelerate adoption and manage payer expectations effectively.

A transparent mixed-methods research approach combining primary expert insights, rigorous secondary source validation, and scenario analysis to ensure actionable findings

The research methodology underpinning this report integrates primary qualitative interviews with clinical experts, payers, and commercialization leaders, secondary literature review across peer-reviewed journals and regulatory documents, and structured synthesis of diagnostic and therapeutic pipelines. Primary input included semi-structured interviews with oncology clinicians, hospital pharmacists, and market access specialists to validate clinical pathways, identify adoption barriers, and surface payer evidence priorities. Secondary research encompassed regulatory guidance documents, clinical trial registries, and published outcome studies to corroborate therapeutic efficacy, safety profiles, and diagnostic utility.

Data synthesis applied triangulation methods to reconcile divergent perspectives and to distill practical implications for development and commercialization. The methodology also incorporated scenario analysis to explore supply chain and policy contingencies and expert validation rounds to ensure interpretive rigor. Transparency of assumptions and a documented audit trail of sources support reproducibility and enable clients to align the findings with internal evidence and strategic planning processes.

Consolidated insights emphasizing diagnostic-driven personalization, evidence-aligned development, and supply chain resilience as pillars for sustained commercial success

In conclusion, the advanced recurrent ovarian cancer ecosystem is at an inflection point where diagnostic-led personalization, therapeutic innovation, and payer-driven evidence demands intersect to reshape clinical and commercial pathways. Stakeholders that proactively integrate biomarker strategies, prioritize evidence generation aligned with payer needs, and optimize delivery models that favor patient-centric administration options will gain competitive advantage. Moreover, resilience in supply chain design and adaptive regional strategies are essential to navigate policy-related cost pressures and heterogeneous reimbursement landscapes.

Ultimately, the synthesis presented here should guide clinical development prioritization, commercialization sequencing, and cross-functional alignment to capture sustainable value. Decision-makers can use these insights to refine go-to-market plans, focus investment in high-impact evidence generation, and build partnerships that enhance diagnostic-enabled patient identification and access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Advanced Recurrent Ovarian Cancer Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Non-Platinum Agents
    • 8.1.2. Platinum Based Agents
  • 8.2. Hormone Therapy
    • 8.2.1. Aromatase Inhibitors
    • 8.2.2. Estrogen Receptor Modulators
  • 8.3. Immunotherapy
    • 8.3.1. Cancer Vaccines
    • 8.3.2. Checkpoint Inhibitors
  • 8.4. Surgery
  • 8.5. Targeted Therapy
    • 8.5.1. Anti Angiogenic Agents
    • 8.5.2. Parp Inhibitors

9. Advanced Recurrent Ovarian Cancer Market, by Administration Route

  • 9.1. Intraperitoneal
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Advanced Recurrent Ovarian Cancer Market, by Line Of Therapy

  • 10.1. Fourth And Beyond
  • 10.2. Second Line
  • 10.3. Third Line

11. Advanced Recurrent Ovarian Cancer Market, by Biomarker Status

  • 11.1. Homologous Recombination Deficiency Negative
  • 11.2. Homologous Recombination Deficiency Positive

12. Advanced Recurrent Ovarian Cancer Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Cancer Centers
  • 12.3. Hospitals
  • 12.4. Specialty Clinics

13. Advanced Recurrent Ovarian Cancer Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Advanced Recurrent Ovarian Cancer Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Advanced Recurrent Ovarian Cancer Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Advanced Recurrent Ovarian Cancer Market

17. China Advanced Recurrent Ovarian Cancer Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bayer AG
  • 18.9. Boehringer Ingelheim International GmbH
  • 18.10. Bristol Myers Squibb Company
  • 18.11. Celsion Corporation
  • 18.12. Clovis Oncology Inc.
  • 18.13. Debiopharm International SA
  • 18.14. Eli Lilly and Company
  • 18.15. Exelixis Inc.
  • 18.16. F. Hoffmann-La Roche Ltd.
  • 18.17. Genentech Inc.
  • 18.18. GlaxoSmithKline plc
  • 18.19. ImmunoGen Inc.
  • 18.20. Johnson & Johnson Services, Inc.
  • 18.21. Kintara Therapeutics Inc.
  • 18.22. Merck & Co., Inc.
  • 18.23. Mirati Therapeutics Inc.
  • 18.24. Novartis AG
  • 18.25. Pfizer Inc.
  • 18.26. Regeneron Pharmaceuticals Inc.
  • 18.27. Sanofi S.A.
  • 18.28. Takeda Pharmaceutical Company Limited
  • 18.29. Vivesto AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY NON-PLATINUM AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ESTROGEN RECEPTOR MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ESTROGEN RECEPTOR MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ESTROGEN RECEPTOR MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI ANGIOGENIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI ANGIOGENIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ANTI ANGIOGENIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAPERITONEAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY FOURTH AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY FOURTH AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY FOURTH AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY NEGATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY NEGATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY NEGATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY BIOMARKER STATUS, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ADVANCED RECURRENT OVARIAN CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)